Nova Eye USA Sales Growth Opportunity
Business Segment Overview
ne
Strategy
Key products
Total Addressable
Market
Sales
Manufacturing
Nova Eye Medical, Glaucoma
Develop, market and sell comprehensive portfolio of
glaucoma consumable surgical devices
iTrack™ Advance, iTrack TM, Molteno3,
US$743m(1) with the glaucoma surgical devices
market growing at 15% CAGR over 2022-28(1)
displacing medication
Established infrastructure; direct sales in USA,
Germany, Australia; distributors in key markets
California, USA and Dunedin, New Zealand
IP Status
Patents issued and pending in major markets
Regulatory
Reimbursement
Europe and Mutual Recognition Jurisdiction and
USA (FDA)
Reimbursed by USA Medicare
Strategy
Key products
Total Addressable
Market
Sales
Manufacturing
IP Status
Regulatory
Structure
AlphaRET, AMD
Commercialise unique and proprietary technology
that addresses AMD with funding from a partner
2RT
62 million (2) people worldwide with Intermediate Age-
related Macular Degeneration treatment (iAMD) –
market not addressed.
Sales program to coincide with funding
Adelaide, Australia based contract manufacturing
Patents issued and pending in major markets
CE Mark (iAMD) and diabetic eye disease) in
Europe, Australia, NZ. FDA USA clearance for
diabetic eye disease
AlphaRET is a wholly-owned subsidiary of Nova Eye
Medical Limited.
(1)
Marketscope 2023 Glaucoma Surgical Device Market Report, 2024 estimate incorporating stents, canal surgery and glaucoma drainage devices, growth through to 2028
(2) Estimate made by Nova Eye based on the results of clinical studies and Marketscope 2022 Ophthalmic Lasers Market Report, 2024 estimate
nova-eye.com | 6View entire presentation